Close menu




June 24th, 2022 | 11:19 CEST

TUI, Pathfinder Ventures, Lufthansa - The travel market is back - where are the share prices?

  • travel
  • Investments
  • Camping
Photo credits: pixabay.com

The travel market has changed dramatically since 2019 in light of the Corona pandemic. Due to the most extensive pandemic standstill in 2020, the capacities for flights, rail traffic and accommodation were adjusted downwards dramatically. Major cost reductions occurred primarily through de-occupancy and staff reductions. Travel companies cut their basic capacity utilization with partners to such an extent that many smaller operations had to pull out of the race, and large corporations could only survive with extensive state aid. Now, however, the situation has turned 180 degrees and demand for travel is exploding. However, this time it seems difficult to ramp up the reduced capacities in line with demand. We look at the opportunities of three typical industry players.

time to read: 5 minutes | Author: André Will-Laudien
ISIN: TUI AG NA O.N. | DE000TUAG000 , PATHFINDER VENTURES INC | CA70323P1071 , LUFTHANSA AG VNA O.N. | DE0008232125

Table of contents:


    TUI - With major Russian shareholder into an uncertain future

    Russian money is invested to a large extent in the West. Whether it is soccer clubs, hotels, real estate or industrial holdings, investors from the East can be found everywhere. This is understandable because Western investments are not only beautiful, they usually increase in value and please the investor. But now there are painful sanctions, and with these, the West wants to hit the Russian economy. But in many cases, things are going differently.

    The oligarchs associated with Russian President Vladimir Putin, in particular, are a target in this economic war. Numerous European companies are also affected, including the German TUI. This is because the family of oligarch Alexei Mordashov holds around 30% of the shares in the Hanover-based travel group. The legal consequences of the sanction affect the Company itself because the Company is not allowed to do anything that gives the sanctioned shareholder any advantages. As a result, all internal activities at TUI have to be reviewed several times, a balancing act for the Company's compliance department and an imposition for all other shareholders who have always stood by TUI.

    It is not yet known how the travel group now intends to deal with its friendly majority shareholder in the long term. Operationally, things should gradually improve, with bookings for the important summer season picking up significantly and, since the beginning of February, have even been above the level of the pre-crisis weeks in 2019, according to the German Travel Association (DRV). TUI expects a "perfect" vacation season for Mallorca in the first summer without Corona conditions. After a repeated emergency capital increase at EUR 2.65, the share price is heading downwards again. A new all-time low of EUR 1.66 was recently reached. The share remains highly speculative, and the massive mountain of debt has long since surpassed the market capitalization. Continue to watch only!

    Pathfinder Venture - New concepts for the post-pandemic world

    An interesting vacation investment can be found in Canada and Frankfurt on the price list, as campground operator Pathfinder Ventures is in the process of occupying an entire niche market with new travel concepts. The historically grown market for camping and RVs experienced a veritable explosion in and after the Corona pandemic. Everything had to be digitized as quickly as possible and set up to meet the needs of a new form of family vacation. Digital booking platforms, modern reservation systems and entertainment offerings for young and old were installed virtually overnight at historically grown sites. Those who wanted to travel in 2020 and 2021 could only do so with months of preparation.

    Pathfinder is developing a network of premier, upscale, family-friendly RV parks and campgrounds under the name "Pathfinder Camp Resorts". Currently, the Company has three camp resorts in British Columbia. Operationally, management is focused on consolidating the particularly fragile market and expanding its inventory of rental sites and mobile homes. In doing so, it is fully targeting the leisure needs of Canadians and long-distance travellers who want to enjoy blanketed nature and privacy in the vastness of North America. Since the beginning of the Corona pandemic alone, the camping tourism market has been growing at rates in excess of the 20% mark. So there is still a lot of potential here because the demand for peace and unspoiled nature has become much higher, not least due to the warlike activities in Europe. Many Europeans are looking for attractive distant destinations to escape the crisis situation in Europe, at least temporarily.

    In the medium term, therefore, it can be expected that both domestic and intercontinental tourism in Canada will continue to grow. The share of camping in North America is not yet as high as in Europe, with around 11.5 million people from Germany indicating that they favour camping as a vacation in 2021. For the still young Pathfinder Ventures, this is a found area for good ideas in the accommodation and leisure sector. Because of the high investments, a planned loss was still made in the first quarter, but the signs continue to point to growth. The microcap is valued at just under EUR 4 million.

    Lufthansa - First capacity cuts, now sheer chaos

    Anyone who boards a Lufthansa flight at the moment gets to see the whole drama of flying, live. Considerable delays, postponed take-offs and cancellations at short notice result when an airline sells a lot of flights on the Internet - indeed, aircraft are significantly overbooked - and then fails due to its own or third-party logistics at the airport.

    You will hear the details if you ask the people on the ground. First, far too many people were cut from all airlines and airport staff due to the pandemic. The urgent need to hire new people is causing significant problems because the "former employees" have looked for a new job or are no longer willing to compete at 2019 rates today. That leads to dramatic understaffing in all positions, extreme stress and absences among existing staff, and ultimately a high level of uncertainty for passengers as to whether they can really fly at the booked time or whether they will arrive on time with their baggage.

    If these conditions cannot be improved as quickly as possible, the German benchmark company in air traffic is threatened with losing its regular customers. Air France-KLM have similar problems, but there are also enough positive counterexamples that have found better solutions in the pandemic. The whole plight of the crane line can be seen in its share price. Minus 40% in the past 36 months and more than EUR 1 billion of necessary government bailout. Investors do not know whether the share price is too low or the final crash landing is yet to come. However, if the EUR 5.50 mark holds, the sky would be blue again for further climbs towards EUR 11 if the EUR 8.50 line is crossed.


    The Ukraine crisis keeps the world on tenterhooks and stirs up bitterness. The almost daily increase in the price of energy is producing economic fears for the future. In this environment, travel and transport companies have a hard time despite numerous catch-up effects. The small Pathfinder Ventures is in a highly dynamic field and is growing prosperously.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    André Will-Laudien

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read